Mizuho Securities Raises Price Target on Jazz Pharmaceuticals (JAZZ) Ahead of 2Q
Get Alerts JAZZ Hot Sheet
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 19
Join SI Premium – FREE
Mizuho Securities reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and raised the price target to $195.00 (from $193.00), ahead of 2Q. Mizuho model revenues of $361.7M and EPS of $2.76 relative to consensus estimates $376.2M and $2.80.
Analyst Irina Koffler commented, "We reiterate our Buy rating on JAZZ heading into 2Q:16 due to continued optimism about the Xyrem litigation/settlements and stronger than expected performance of Defitelio in the U.S. We raise our PT to $195 from $193."
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $142.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Bank Jago Tbk PT (ARTO:IJ) to Overweight
- ASML Holding NV (ASML:NA) (ASML) PT Raised to EUR1,100 at Berenberg
- Morgan Stanley Downgrades Etsy (ETSY) to Underweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!